Beam Therapeutics Inc. Insider Transaction

Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc., reported a sale of 3,242 shares of common stock on April 1, 2026. The sale, valued at approximately $79,669 (3,242 shares at $24.58 per share), was executed to cover tax withholding obligations upon the vesting of restricted stock units. These transactions were part of a non-discretionary sale under a Rule 10b5-1 trading plan adopted on August 9, 2024. Following this transaction, Ms. Cavanagh holds 51,171 shares of Beam Therapeutics common stock.